We serve Diethyl chloromalonate CAS:14064-10-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
USD:A compound used in the models of aquatic toxicity developed (QSAR). Combinatorial QSAR modeling of chemical toxicants tested against Tetrahymena pyriformis.
| Items of Analysis | Standard of Analysis | Test Results |
| Appearance | Colorless transparent liquid | Conform |
| Assay | ≥97.0% | 97.61% |
| Conclusion | Conforms to Factory Standard | |
Contact us for information like Diethyl chloromalonateDiethyl 2-chloromalonate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Propanedioic acid, chloro-, diethyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Propanedioic acid, chloro-, diethyl ester Use and application,Propanedioic acid, chloro-, diethyl ester technical grade,usp/ep/jp grade.
Related News: From basic chemical raw materials to chemical preparations, complex chemical and physical processes are required. The production of chemical raw materials and intermediates concentrates the main synthetic procedures and technical links, which is the prerequisite and important guarantee for the development of the chemical pharmaceutical industry.4-(14,24-trioxidan-1-ynyl)-26,43,54,64-heptaoxid-5-yne-2,2-dione manufacturer From basic chemical raw materials to chemical preparations, complex chemical and physical processes are required. The production of chemical raw materials and intermediates concentrates the main synthetic procedures and technical links, which is the prerequisite and important guarantee for the development of the chemical pharmaceutical industry.4-methoxy-7-methyl-benzo[1,2,5]thiadiazole supplier Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). 3-[[[[3-[(aminocarbonyl)amino]phenyl]carbonyl]amino]methyl]benzenepropanoic acid vendor Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML). Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).
